Pharmaceutical exporters · Export-oriented and SEZ units
What each export market really pays a pharmaceutical exporter
A pharmaceutical exporter can show strong export sales while cash from several markets is months overdue and partner settlements are unchecked. We measure realisation by country, product and partner, track what it costs to keep each product registered in each market, and keep export receivables inside the limits that protect them.
In one paragraph
Formulation and API manufacturers and merchant exporters sell into very different markets: regulated ones such as the US and Europe, and emerging ones across Africa, Latin America and Asia. We work with their owners and finance heads, usually at ₹25–1,000 crore turnover. The focus is the export side: markets, partners, receivables and incentives. Batch costing and plant economics sit on the pharmaceutical manufacturing pages.
Managing director or chief financial officer, often with the head of international business
The economics
How the money moves in this trade
Pharmaceutical exports reach each market through a different arrangement. In regulated markets, products are often sold through a marketing partner on a supply price plus a share of the partner's profit. That share is settled after the partner deducts its own costs, rebates and returns. In many emerging markets products go to distributors on long credit, sometimes where currency controls delay payment, and export credit insurance may be the only real protection.
Before any of this, each product must be registered in each market, at a cost that runs for years before the first sale and recurs for renewals and variations. Exporters must also realise export proceeds within the period FEMA allows and keep the shipping bills and remittances matched. A business can look profitable in aggregate while one or two markets consume most of its working capital.
The problem
Where the numbers usually break down
Partner profit-share statements are accepted as sent
Settlements from marketing partners are booked from the partner's statement without checking deductions for rebates, returns and partner expenses against the agreement.
Receivables are not tracked by country risk
Distributor balances in markets with currency or payment delays are aged together with prompt-paying markets, so concentration risk is hidden.
Registration cost is not linked to markets
Dossier, filing and renewal costs are expensed as incurred, so nobody can compare the cost of a registration with the sales it produced.
Unrealised shipping bills accumulate
Shipping bills awaiting realisation are followed up only when the bank raises them, and part-payments are not matched invoice by invoice.
Insurance cover does not match exposure
Export credit insurance limits per buyer are not compared with what that buyer actually owes, leaving gaps when a buyer defaults.
What we do
The work, and the result each part produces
Partner settlement review
Each partner's profit-share or royalty statement tested against the agreement, with deductions for rebates, returns and expenses checked line by line.
Partner settlements are verified before they are booked.
Market and product realisation
Net realisation by country, partner and product after freight, partner deductions, insurance and credit cost.
Each market is judged on what it actually pays.
Registration cost by product and market
Dossier, filing, renewal and variation costs recorded against each product-market registration and compared with sales.
Registration decisions are made with their full cost known.
Export receivable control
Receivables aged by market, distributor and insurance cover, with dispatch holds where exposure exceeds limits.
Exposure to slow-paying markets is capped.
Shipping bill realisation tracking
Each shipping bill matched to remittances, with part-payments, bank charges and short receipts classified.
Unrealised bills are known before the bank asks.
Incentive and refund records
Drawback, remission and IGST refund claims tracked from shipment to receipt.
Export incentives due are claimed and collected.
Where we start
The first steps of an engagement
Shipping bills, partner statements, agreements
We ask for the shipping bills pending realisation, partner profit-share or royalty statements with the agreements behind them, distributor ledgers and the export credit insurance policy.
Partner statements tested line by line
Recent partner statements are tested against the agreement for rebates, returns and expenses. Shipping bills are matched to remittances invoice by invoice.
Receivable limits by market
Receivables are aged by market and distributor against insurance cover. A dispatch-hold rule is agreed for buyers who go beyond their limit.
First market realisation report
Net realisation by market, partner and product, the partner deductions that do not match the agreement, and the shipping bills still open for realisation.
How it is measured
The reports the work is judged on
Each is recorded as a baseline before the work starts, so later reports have an honest comparison.
- Net realisation by market, partner and product
- Partner deductions tested against agreement terms
- Export receivables by market, aged against insurance cover
- Registration cost against sales, by product and market
- Shipping bills outstanding for realisation
- Incentive and refund claims outstanding
Who it suits
Written for, and not the right fit for
- You need regulatory dossiers prepared or product registrations filed — that is specialist regulatory work.
- Your question is plant cost and batch yield rather than export markets — the pharmaceutical manufacturing pages cover that.
- Formulation and API manufacturers with a significant share of export sales.
- Exporters working through marketing partners on profit-share or royalty terms.
- Firms with large receivables in emerging markets or delays in realising export proceeds.
Cities where this trade concentrates
Services
Services this work draws on
SEZ and foreign trade advisory
SEZ, EOU and export scheme records kept continuously, not at assessment.
Explore service ↗MIS and financial planning
Reporting built around the questions you actually need answered.
Explore service ↗Internal controls and risk
Controls sized to your business, documented and actually tested.
Explore service ↗Fractional CFO services
Senior financial leadership on the days you need it, not a full-time hire.
Explore service ↗Every other service, also available in this trade
Common questions
Questions owners in this trade ask
Our partner's statement is audited. Why check it?
Because the audit covers the partner's books, not whether the deductions match your agreement. Rebates, returns and expense allocations are where profit-share settlements usually drift, and only you have the agreement to test them against.
What happens if export proceeds are not realised in time?
Your bank follows it up, and any extension or write-off goes through the bank under FEMA rules. The permitted period has changed more than once recently, so check the current one with your bank. We track every shipping bill against remittances and prepare the information the bank needs.
Do you also cover plant costing?
That's on our pharmaceutical manufacturing pages. The export work is about what happens after the goods leave: markets, partners, receivables and incentives.
Product registrations and regulatory filings in each market are the client's own responsibility. Realisation extensions and write-offs are handled through the client's authorised dealer bank. Certificates for incentive or refund claims, transfer-pricing reports and statutory audit reports are issued by an independently engaged CA; 5th Quadrant prepares the records behind them. Full detail is on our Professional Scope page.
Explore further